GSK’s Avandia to be hit by near-blanket ban

Published: 2010-09-29 06:59:00

Updated: 2010-09-29 06:59:00

The Korea Food and Drug Administration will deal a powerful blow to GlaxoSmithKline by issuing a near-blanket ban on sales of Avandia, the UK pharmaceutical group’s top-selling diabetes drug, according to market insiders.

In a statement on September 24, the drug agency said it would restrict A...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK